2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
37
Phase 4
31
Phase 2
19
Phase 3
16
Phase 2/3
4
Phase 1/2
4
Phase 1
2
Phase EARLY_PHASE1
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
626
pembrolizumab
505
Paclitaxel
456
Gemcitabine
439
Carboplatin
437
Cisplatin
420
Radiotherapy
382
fludarabine
367
Nivolumab
340
Docetaxel
278
Bevacizumab
276
Irinotecan
258
Magnetic Resonance Spectroscopy
245
Fluorouracil
229
Dexamethasone
225
Specimen Handling
223
Capecitabine
218
Rituximab
206
Oxaliplatin
201
Cytarabine
201
Ipilimumab
198
Temozolomide
197
Biopsy
197
fludarabine phosphate
194
Etoposide
181
Lenalidomide
176
Doxorubicin
175
Leucovorin
174
Cetuximab
171
Injections
170
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Bupivacaine
×
Clear all
NCT03177252
2020-10-22
Scalp block
Washington University School of Medicine
Phase 1
Withdrawn
NCT02681796
2020-03-12
E-PRO I
Washington University School of Medicine
Phase 1
Completed
23 enrolled